BHA (Butylated Hydroxyanisole): FDA Reassessment, Carcinogen Classification & State Bans

What Is BHA?

Butylated hydroxyanisole (BHA), also known as tert-butyl-4-hydroxyanisole (CAS 25013-16-5, UNII: REK4960K2U), is a synthetic phenolic antioxidant used primarily to prevent oxidative rancidity in fats, oils, and fat-containing foods. It has been part of the U.S. food supply since the late 1940s and was classified as Generally Recognized as Safe (GRAS) by the FDA in 1958.

BHA is a waxy white solid, typically a mixture of two isomers (2-tert-butyl-4-hydroxyanisole and 3-tert-butyl-4-hydroxyanisole), and functions by scavenging free radicals that initiate lipid oxidation. It is frequently used in combination with butylated hydroxytoluene (BHT) and propyl gallate for synergistic antioxidant effects. Beyond food, BHA appears in cosmetics, pharmaceuticals, rubber, petroleum products, and food packaging materials.

BHA is distinct from BHT (butylated hydroxytoluene), though the two are often discussed together and used in combination. BHA is also distinct from TBHQ (tert-butylhydroquinone), another synthetic antioxidant under separate regulatory scrutiny.

As of early 2026, BHA is the subject of an active FDA post-market safety reassessment and features prominently in federal and state-level legislative efforts to reform food chemical oversight.

FDA Regulatory Status

1. GRAS listing under 21 CFR 182.3169 — BHA is Generally Recognized as Safe for use as a chemical preservative in food, subject to the limitation that the total antioxidant content of food (including BHA) must not exceed 0.02% of the fat or oil content of the food, including the essential (volatile) oil content of the food.

2. Food additive regulation under 21 CFR 172.110 — BHA is authorized as a direct food additive when used as an antioxidant, alone or in combination with BHT and/or propyl gallate, in specific food categories with defined maximum use levels.

BHA was first listed as GRAS in 1958 under the original GRAS list established by the Food Additives Amendment. It received food additive approval in 1961 for uses beyond the GRAS limitations. BHA is also authorized as an indirect food additive in food-contact materials (food packaging), regulated under 21 CFR Parts 175-178.

Critically, BHA is not a color additive. The Delaney Clause — which mandates automatic ban of any color additive found to cause cancer in animals — does not apply to BHA. Any potential FDA action on BHA would proceed through the food additive safety evaluation framework, which permits risk-based assessment rather than the zero-tolerance standard applied to color additives like Red No. 3.

FDA Post-Market Reassessment (February 2026)

On February 10, 2026, the FDA announced a formal post-market reassessment of BHA. The Request for Information (RFI) was published in the Federal Register on February 11, 2026 (91 FR 6227, Docket No. FDA-2026-N-0302). The RFI seeks:

• General food categories in which BHA is currently used
• Typical and maximum use levels in each food category
• Current dietary exposure estimates
• Relevant safety data, including toxicological studies

The public comment deadline is April 13, 2026.

This reassessment was triggered by FDA's enhanced post-market chemical review program, announced in May 2025, which established a systematic framework for re-evaluating chemicals already in the food supply. The FDA identified BHA as a top priority for review, alongside BHT and azodicarbonamide. The agency cited the National Toxicology Program's carcinogenicity classification and the age of BHA's original safety evaluation as factors in its prioritization.

The reassessment will evaluate whether BHA remains safe under its current authorized conditions of use, considering the totality of available scientific evidence. Possible outcomes range from reaffirmation of current authorizations to revised use limits, additional labeling requirements, or revocation of authorization — though any formal regulatory action would require a separate rulemaking process.

Carcinogenicity Classifications

BHA carries two significant carcinogenicity designations from U.S. and international health authorities:

NTP — "Reasonably Anticipated to Be a Human Carcinogen"

The National Toxicology Program (NTP), part of the National Institutes of Health, has listed BHA as "reasonably anticipated to be a human carcinogen" since the Sixth Annual Report on Carcinogens (1991). This classification was most recently reaffirmed in the 15th Report on Carcinogens (December 2021). The basis:

• Dietary BHA caused benign and malignant forestomach tumors (papilloma and squamous-cell carcinoma) in rats of both sexes and in male mice and hamsters
• Dietary BHA in fish larvae (hermaphroditic Rivulus marmoratus) caused hepatocellular carcinoma in adult fish
• Epidemiological data in humans are inadequate to evaluate the relationship

IARC — Group 2B ("Possibly Carcinogenic to Humans")

The International Agency for Research on Cancer (IARC) classified BHA as Group 2B in 1987 (IARC Monographs Supplement 7, based on data reviewed in Volume 40, 1986), based on sufficient evidence of carcinogenicity in experimental animals and inadequate evidence in humans.

The Forestomach Question

A central point in the BHA safety debate is that the primary tumor site — the rodent forestomach — has no anatomical equivalent in humans. Both EFSA and various industry-funded reviews have argued that the forestomach tumors are species-specific and not relevant to human risk assessment. However, neither the NTP nor IARC has withdrawn its classification. The NTP has noted that tumor formation in the forestomach represents a local response to a chemical insult, and the absence of a human forestomach does not eliminate the possibility of comparable effects in the human esophagus or other squamous epithelial tissues.

California Proposition 65

BHA has been listed on the California Proposition 65 list as a known carcinogen since January 1, 1990. The listing was based on the IARC Group 2B classification. Under Proposition 65 (the Safe Drinking Water and Toxic Enforcement Act of 1986), businesses selling products containing BHA in California must provide a clear and reasonable warning to consumers about potential exposure, unless the exposure falls below the established No Significant Risk Level (NSRL).

OEHHA (the California Office of Environmental Health Hazard Assessment) has not established a specific NSRL for BHA through dietary exposure, which means food manufacturers must either provide warnings or demonstrate that exposure falls below a calculated threshold using the default risk assessment methodology.

State-Level Legislation

West Virginia — HB 2354

Governor Patrick Morrisey signed HB 2354 into law on March 24, 2025. The law is structured in two phases:

• Phase 1 (effective August 1, 2025): Prohibits seven synthetic color additives (Red 3, Red 40, Yellow 5, Yellow 6, Blue 1, Blue 2, Green 3) from school nutrition programs.
• Phase 2 (effective January 1, 2028): Bans the sale of foods and drugs containing those same dyes plus BHA and propylparaben statewide.

Current status — preliminary injunction: In December 2025, U.S. District Judge Irene Berger granted a preliminary injunction blocking enforcement of the Phase 2 provisions (including the BHA ban), finding the law unconstitutionally vague. The injunction specifically targeted the law's use of undefined terms like "poisonous and injurious" and its non-exclusive list structure using the term "including." The Phase 1 school meal provisions remain in effect and are not subject to the injunction. The case is ongoing.

Other State Activity

West Virginia's law represents the first state-level attempt to ban BHA specifically. California's AB 418 (the California Food Safety Act) does not include BHA — it covers Red No. 3, potassium bromate, propylparaben, and brominated vegetable oil. However, the growing legislative momentum around food additive reform at the state level creates an environment where BHA bans could appear in additional state bills, particularly given the FDA's active reassessment.

Federal Legislation

Food Chemical Reassessment Act of 2025 (H.R. 4306)

Introduced by Representatives Schakowsky and DeLauro, H.R. 4306 would require the FDA's Office of Food Chemical Safety, Dietary Supplements, and Innovation to systematically reassess the safety of at least 10 listed chemicals every three years, beginning in 2026. BHA is explicitly named on the bill's priority list alongside:

• TBHQ (tert-butylhydroquinone)
• Titanium dioxide
• Red 40, Yellow 5, Blue 1, Blue 2, Green 3
• Perchlorate
• BHT
• Trichloroethylene, methylene chloride, benzene, ethylene chloride
• Propyl gallate, sodium nitrite, sodium benzoate

The bill remains in committee as of March 2026. Even without passage, it signals sustained Congressional interest in food chemical oversight and may apply political pressure that accelerates FDA's administrative review of BHA.

MAHA Initiative

The Make America Healthy Again (MAHA) Commission, chaired by HHS Secretary Robert F. Kennedy Jr. and established in February 2025, has driven significant FDA activity on food chemical safety. While the MAHA report's primary focus has been on synthetic color additives, artificial sweeteners, and specific additives like titanium dioxide and propylparaben, the broader MAHA-aligned regulatory posture has accelerated the FDA's chemical review program — including the BHA reassessment announced in February 2026. The FDA explicitly framed the BHA review as part of its MAHA-aligned efforts to ensure food supply safety.

International Regulatory Status

European Union — E320

BHA is authorized in the EU as food additive E320 under Commission Regulation (EU) No 231/2012, with an acceptable daily intake (ADI) of 1.0 mg/kg body weight per day, established by EFSA in its 2011 re-evaluation. BHA is permitted in specific food categories with defined maximum levels, including fats and oils, processed nuts, dry cereals, soup concentrates, confectionery, meat products, and chewing gum.

EFSA's 2011 Scientific Opinion concluded that BHA is not genotoxic, that the forestomach tumors observed in rodents are not relevant to humans (due to species-specific anatomy), and that reproductive toxicity data did not raise concerns at current exposure levels. EFSA set the ADI based on a NOAEL of 100 mg/kg bw/day for developmental effects in rats, applying a 100-fold uncertainty factor.

JECFA (Joint FAO/WHO Expert Committee on Food Additives)

JECFA has evaluated BHA multiple times (1961, 1965, 1973, 1976, 1982, 1989). The current JECFA ADI is 0-0.5 mg/kg body weight per day, set in 1989 based on a NOAEL of 50 mg/kg bw/day for forestomach hyperplasia in rats with a 100-fold uncertainty factor. The JECFA ADI is more conservative than EFSA's by a factor of two, reflecting differing interpretations of the same underlying toxicological data.

Other Jurisdictions

• Japan: BHA use is restricted; it was proposed for a ban in 1982 but ultimately allowed in limited applications after industry lobbying.
• Canada: BHA is permitted as a food additive under the Food and Drug Regulations, with use limits similar to U.S. standards.
• Codex Alimentarius: BHA is included in the General Standard for Food Additives (GSFA) with specified maximum use levels.

Affected Product Categories

BHA is found across a broad range of product categories. The Environmental Working Group (EWG) has identified BHA in over 4,600 food products currently on the U.S. market, including:

• Breakfast cereals: Both in the cereal itself and in inner packaging liners
• Snack foods: Potato chips, crackers, and other fried or oil-containing snacks
• Baked goods: Shortening, pie crusts, and shelf-stable bakery items
• Processed meats: Sausages, jerky, and other cured or preserved meats
• Fats and oils: Lard, tallow, and vegetable oils for commercial frying
• Frozen and prepared meals: TV dinners, frozen pizzas, and convenience foods
• Confectionery: Chewing gum, candy bars with fat-based coatings
• Food packaging: Wax coatings, plastic wraps, and paperboard liners where BHA migrates into food as an indirect additive
• Cosmetics and personal care: Lipsticks, moisturizers, and other products (regulated by FDA under cosmetic authorities, not food additive rules)
• Pharmaceuticals: Excipient in capsules and tablet coatings

Natural Alternatives

The food industry has been steadily transitioning toward natural antioxidant alternatives, driven by clean-label consumer demand and regulatory pressure. Viable replacements for BHA include:

• Rosemary extract (carnosic acid / carnosol): The most widely adopted natural alternative. Effective in oils, snack foods, and meat products. FDA GRAS and EFSA-approved. Thermally stable up to 180 degrees C.
• Mixed tocopherols (Vitamin E): Effective in vegetable oils, cereals, and beverages. FDA GRAS. Available as d-alpha, gamma, and delta tocopherol blends. Less effective than BHA at high temperatures.
• Ascorbyl palmitate (Vitamin C ester): Oil-soluble form of ascorbic acid. Synergistic with tocopherols. Used in oils and fat-containing products.
• Green tea extract (catechins): Emerging alternative with antioxidant and antimicrobial properties.

Cost and performance tradeoffs: Natural alternatives are generally 2-5x more expensive than BHA on a per-unit basis and may require reformulation to achieve equivalent shelf-life extension. Rosemary extract can impart a slight herbal note in bland products. Mixed tocopherols degrade faster at frying temperatures. However, the clean-label premium and reduced regulatory risk increasingly offset these disadvantages.

What Companies Should Watch

1. April 13, 2026 — FDA comment deadline. The RFI response window is the immediate action item. Companies currently using BHA in food or food-contact materials should consider submitting use and safety data. Industry trade groups (GMA, FMI) are expected to coordinate responses.

2. FDA reassessment outcome (timeline TBD). The reassessment could result in affirmed safety, revised use limits, new labeling requirements, or initiation of revocation proceedings. Any formal regulatory change would require notice-and-comment rulemaking, meaning years before implementation — but the signal value of the reassessment is immediate.

3. West Virginia HB 2354 litigation. The preliminary injunction blocking the Phase 2 BHA ban is not a final ruling. If the state prevails or the law is amended to address vagueness concerns, a January 2028 ban date remains possible.

4. H.R. 4306 movement. The Food Chemical Reassessment Act would institutionalize periodic review of BHA and 16 other chemicals. Even without passage, the bill reflects bipartisan momentum on food chemical reform.

5. Voluntary reformulation wave. Major food manufacturers are already replacing BHA with rosemary extract and tocopherols in response to consumer pressure and retailer clean-label requirements, independent of regulatory mandates. Companies that have not begun reformulation planning may face competitive disadvantage and supply chain constraints as demand for natural alternatives increases.

6. Cross-jurisdictional compliance. Companies selling into both the U.S. and EU markets must track divergent ADI values (JECFA 0.5 vs. EFSA 1.0 mg/kg bw/day) and country-specific use limits. The FDA reassessment could narrow or widen the gap with international standards.